• Rodolfo Rivas-Ruiz, Kingston Ureña-Wong, Osvaldo Daniel Castelán-Martínez, Yadira Betanzos-Cabrera, César Lazo-Cárdenas, César Ramírez-Portillo, and Enrique López-Aguilar.
• Instituto Mexicano del Seguro Social, Center of Clinical Training and Research, Health Research Coordination. Mexico City, Mexico.
• Gac Med Mex. 2020 Jan 1; 156 (3): 217-223.

IntroductionCardiotoxicity is an adverse reaction associated with the use of anthracyclines.ObjectiveTo estimate the factors associated with the development of anthracycline cardiotoxicity in pediatric patients surviving cancer.MethodRetro-prolective cohort of children diagnosed with cancer and treated with anthracyclines. Baseline echocardiographic determination of ejection fraction (LVEF0) was carried out before the start of treatment and again at 12 months (LVEF1). Demographic characteristics and treatment were obtained from the medical record. A multiple logistic regression (MLR) model was constructed; LVEF1 < 50 % was the dependent variable, which was adjusted for the main confounding variables.ResultsSixty-five patients were included, out of which 36.9 % were females and 56.8 % had a solid tumor. LVEF0 was 74.79 ± 7.3 % and LVEF1, 67.96 ± 6.7 % (p = 0.001); 60 % developed cardiotoxicity. In the MLR, only a cumulative dose > 430 mg was associated with cardiotoxicity (p = 0.001).ConclusionsIn Mexican children, an anthracycline cumulative dose > 430 mg should be avoided in order to prevent cardiotoxicity.Copyright: © 2020 Permanyer.

26 keywords...

hide…